Yang Su is a strategic scientist and project leader known for developing antibody-drug conjugates (ADC) and antibody-based cancer therapeutics. They held positions as a Postdoctoral Scholar at UCSF from 2010 to 2015, followed by roles as an Assistant Professional Researcher and Assistant Specialist at the University of California, San Francisco, from 2016 to 2021. Yang then served as a Senior Scientist at RemeGen Biosciences from 2021 to 2022 before becoming a Principal Scientist at Bristol Myers Squibb, where they worked until 2024. Currently, Yang is the Associate Director of Oncology (ADC Biology) at insitro. They are also pursuing degrees at Nanjing Agricultural University and the University of California, San Francisco, in addition to holding a Ph.D. from Fudan University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices